Back to Authors

Badar, Talha

https://orcid.org/0000-0003-1548-918X

A5079157559 | I4210146710

Mayo Clinic in Florida

Citations 184

Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6940-6941

10.1182/blood-2022-163518

Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9675-9676

10.1182/blood-2022-163485

Clinical and Genetic Characteristics of STAG2 Mutations in Myeloid Neoplasms

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12353-12354

10.1182/blood-2022-155561

Outcomes of Adults Treated with a Hypomethylating Agent Plus Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia: A Multicenter Retrospective Study

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6187-6188

10.1182/blood-2022-170647

Differential Impact on Survival in Myeloid Neoplasm Patients with U2AF1 Mutations

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9602-9603

10.1182/blood-2022-167405

Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9019-9020

10.1182/blood-2022-168303

The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2887-2890

10.1182/blood-2022-162367

U2AF1 Mutant Clonal Hematopoiesis Is Infrequent, Context Dependent, and Commonly Co-Occurs with BCOR Mutations

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 11408-11409

10.1182/blood-2022-166794

Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1435-1437

10.1182/blood-2022-167731

Clinical and Molecular Characteristics of ETV6 Mutated Myeloid Malignancies

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6912-6914

10.1182/blood-2022-170641